NCT05199688View on ClinicalTrials.gov

A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

PHASE3RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

September 12, 2029

Conditions
Neuromyelitis Optica Spectrum DisorderNMOSD
Interventions
DRUG

Satralizumab

Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period.

Trial Locations (10)

6810

RECRUITING

Kocaeli University Research and Application Hospit, Kocaeli

27100

RECRUITING

Fondazione Istituto Neurologico Mondino IRCCS, Pavia

94275

RECRUITING

Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-Bicêtre

80218-1007

RECRUITING

Children's Hospital Colorado., Denver

C1249ABN

RECRUITING

Hospital de Pediatría S.A.M.I.C.- Prof. Dr. Juan P. Garrahan, Ciudad Autonoma Buenos Aires

X5004FHP

RECRUITING

Clinica Universitaria Reina Fabiola, Córdoba

00165

RECRUITING

IRCCS Ospedale Pediatrico Bambino Gesù - INCIPIT - PIN, Rome

DUMMY_VALUE

RECRUITING

Grupo Medico Camino, DF

80-214

ACTIVE_NOT_RECRUITING

Uniwersyteckie Centrum Kliniczne, Gda?sk

WC1N 3JH

RECRUITING

Great Ormond Street Hospital for Children, London

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY